Hypofractionated radiotherapy for organ-confined prostate cancer: Is less more?

Nature Reviews Urology

Volumn 13, Issue 7, 2016, Pages 400-408

  Arcangeli, Stefano ^a   Greco, Carlo ^a  

^a CHAMPALIMAUD CENTRE FOR THE UNKNOWN   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL RECURRENCE; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; LONG TERM CARE; OVERALL SURVIVAL; PATIENT COMFORT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CANCER; REPRODUCIBILITY; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; CLINICAL TRIAL (TOPIC); MALE; PROCEDURES; PROSTATE TUMOR; STANDARDS;

CLINICAL TRIALS AS TOPIC; DOSE HYPOFRACTIONATION; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84976878606     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2016.106     Document Type: Review

References (77)

1. Staffurth, J. A review of the clinical evidence for intensity-modulated radiotherapy. Clin. Oncol. (R. Coll. Radiol.) 22, 643-657 (2010
2. Dawson, L. A., & Menard, C. Imaging in radiation oncology: a perspective. Oncologist 15, 338-349 (2010
3. Verellen, D., et al. Innovations in image-guided radiotherapy. Nat. Rev. Cancer 7, 949-960 (2007
4. Timmerman, R. D., Kavanagh, B. D., Cho, L. C., Papiez, L., & Xing, L. Stereotactic body radiation therapy in multiple organ sites. J. Clin. Oncol. 25, 947-952 (2007
5. Steel, G. G. (ed.) Basic Clinical Radiobiology (Arnold, 2002
6. Proust-Lima, C., et al. Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-Treatment repeated-measures model for PSA dynamics. Int. J. Radiat. Oncol. Biol. Phys. 79, 195-201 (2011
7. Miralbell, R., Roberts, S. A., Zubizarreta, E., & Hendry, J. H. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β=1.4 (0.9-2.2) Gy. Int. J. Radiat. Oncol. Biol. Phys. 82, e17-e24 (2012
8. Dasu, A., & Toma-Dasu, I. Prostate α/β revisited - an analysis of clinical results from 14168 patients. Acta Oncol. 51, 963-974 (2012
9. Fowler, J. F. The linear-quadratic formula and progress in fractionated radiotherapy. Br. J. Radiol. 62, 679-694 (1989
10. Demaria, S., et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58, 862-870 (2004
11. Rubner, Y., et al. How does ionizing irradiation contribute to the induction of anti-Tumor immunity?. Front. Oncol. 2, 75 (2012
12. Bonner, J. A., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5 year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11, 21-28 (2010
13. Heron, D. E., et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int. J. Radiat. Oncol. Biol. Phys. 75, 1493-1500 (2009
14. Zaorsky, N. G., Ohri, N., Showalter, T. N., Dicker, A. P., & Den, R. B. Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat. Rev. 39, 728-736 (2013
15. Koontz, B F., et al. A systematic review of hypofractionation for primary management of prostate cancer. Eur. Urol. 68, 683-691 (2015
16. Lukka, H., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J. Clin. Oncol. 23, 6132-6138 (2005).
17. Yeoh, E. E., et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 81, 1271-1278 (2011
18. Kuban, D. A., et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int. J. Radiat. Oncol. Biol. Phys. 78, S58-S59 (2010
19. Pollack, A., et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J. Clin. Oncol. 31, 3860-3868 (2013
20. Arcangeli, S., et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 84, 1172-1178 (2012
21. International Standard Randomised Controlled Trial Number Register. www.isrctn.com http://www.isrctn.com/ISRCTN85138529 (2015
22. International Standard Randomised Controlled Trial Number Register. www.isrctn.com http://www.isrctn.com/ISRCTN97182923 (2015
23. US National Library of Medicine. www.clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT00331773 (2016
24. US National Library of Medicine. www.clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT00304759 (2015
25. START Trialists' Group et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371, 1098-1107 (2008
26. START Trialists' Group et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 9 331-341 (2008
27. Whelan, T. J., et al. Long-Term results of hypofractionated radiation therapy for breast cancer. N. Engl. J. Med. 362, 513-520 (2010
28. Aluwini, S., et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 17, 464-474 (2016
29. Lee, W. R., et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2016.67.0448 (2016
30. Incrocci, L., et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5 year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. Int. J. Radiat. Oncol. Biol. Phys. 94, A1-A2 (2016
31. Dearnaley, D. LBA8. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. Eur. J. Cancer 51 S712 2015
32. Collins C. D. Lloyd-Davies R. W., & Swan A. V. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin. Oncol. R. Coll. Radiol.) 3, 127-132 (1991
33. Fuller, D. B., et al. Prospective evaluation of stereotactic body radiation therapy for low-And intermediate-risk prostate cancer: emulating high-doserate brachytherapy dose distribution. Int. J. Radiat. Oncol. Biol. Phys. 84, S149 (2012
34. International Standard Randomised Controlled Trial Number Register. www.isrctn.com http://www.isrctn.com/ISRCTN45905321 (2009
35. Fuller, D. B., Naitoh, J., & Mardirossian, G. Virtual HDR CyberKnife SBRT for localized prostatic carcinoma: 5 year disease-free survival and toxicity observations. Front. Oncol. 4, 321 (2014
36. Madsen, B. L., et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int. J. Radiat. Oncol. Biol. Phys. 67, 1099-1105 (2007
37. Aluwini, S., et al. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat. Oncol. 8, 84 (2013
38. Loblaw, A., et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother. Oncol. 107, 153-158 (2013
39. Kim, D. W. N., et al. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 89, 509-517 (2014
40. King, C. R., Brooks, J. D., Gill, H., & Presti, J. C. Long-Term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 82, 877-882 (2012
41. Bolzicco, G., et al A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol. 13 49 2013
42. Chen, L. N., et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat. Oncol. 8, 58 (2013
43. Oliai, C., et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J. Radiat. Oncol. 2, 63-70 (2013
44. Meier, R., Beckman, A. C., Henning, G., & Mohideen, N. Stereotactic body radiation therapy for intermediate-risk prostate cancer: five-year outcomes from a multi-institutional study. Int. J. Radiat. Oncol. Biol. Phys. 93(3S), S199 (2015
45. Katz, A. J., & Kang, J. Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7 year study. Front. Oncol. 4, 301 (2014
46. Hoppe, B. S., et al. Erectile function, incontinence, and other quality of life outcomes following protontherapy for prostate cancer in men 60 years old and younger. Cancer 118, 4619-4626 (2012
47. Coen, J. J., et al. Long-Term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 82, e201-e209 (2012
48. Demanes, D. J., Rodriguez, R. R., Schour, L., Brandt, D., & Altieri, G. High-dose rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10 year results. Int. J. Radiat. Oncol. Biol. Phys. 61, 1306-1316 (2005
49. Frank, S. J., et al. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J. Urol. 177, 2151-2156 (2007
50. King, C. R., et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother. Oncol. 109, 217-221 (2013
51. King, C. R., et al. Health- related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int. J. Radiat. Oncol. Biol. Phys. 87, 939-945 (2013
52. Sanda, M. G., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358, 1250-1261 (2008
53. Yu, J. B., et al. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J. Clin. Oncol. 32, 1195-1201 (2014
54. Arcangeli, S., De Bari, B., & Alongi, F. Toxicity of stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: a potential comparison bias. J. Clin. Oncol. 32, 3454 (2014
55. Evans, J. R., et al. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother. Oncol. 116, 179-184 (2015
56. US National Library of Medicine. www.clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT01434290 (2015
57. Lukka, H., Stephanie, P., Bruner, D., Bahary, J. P. Lawton, C. A. F., & Efstathiou, J. A. Patient-reported outcomes in NRG Oncology/RTOG 0938, a randomized phase 2 study evaluating 2 ultra hypofractionated regimens (UHRs) for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 94, A2 (2016
58. Widmark, A., et al. SP 0299. Extreme hypofractionation: indications and results. Radiother. Oncol. 119 (Suppl. 1), S139 (2016
59. Wiegner, E. A., & King, C. R. Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 78, 442-448 (2010
60. Bauman, G., Haider, M., Van der Heide, U. A., & Menard, C. Boosting imaging defined dominant prostatic tumors: a systematic review. Radiother. Oncol. 107, 274-281 (2013
61. Pucar, D., et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int. J. Radiat. Oncol. Biol. Phys. 69, 62-69 (2007).
62. Zumsteg, Z. S., et al. Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate cancer. J. Urol. 194, 1624-1630 (2015
63. Kron, T., et al. Intra-fraction prostate displacement in radiotherapy estimated from pre- and post-Treatment imaging of patients with implanted fiducial markers. Radiother. Oncol. 95, 191-197 (2010
64. Kupelian, P., et al. Multi-institutional clinical experience with the Calypso System in localization and continuous, real-Time monitoring of the prostate gland during external radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 67, 1088-1098 (2007
65. Teh, B. S., et al. The use of rectal balloon during the delivery of intensity modulated radiotherapy (IMRT) for prostate cancer: more than just a prostate gland immobilization device?. Cancer J. 8, 476-483 (2002
66. Sanghani, M. V., et al. Impact on rectal dose from the use of a prostate immobilization and rectal localization device for patients receiving dose escalated 3D conformal radiation therapy. Urol. Oncol. 22, 165-168 (2004
67. Van Lin, E. N., Hoffmann, A. L., Van Kollenburg, P., Leer, J. W., & Visser, A. G. Rectal wall sparing effect of three different endorectal balloons in 3D conformal and IMRT prostate radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 63, 565-576 (2005
68. Greco, C. Extreme hypofractionated image-guided radiotherapy (IGRT) for prostate cancer. EMJ Oncol. 1, 48-55 (2013
69. US National Library of Medicine. www.clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT02570919 (2015
70. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Engl. J. Med. 324 1685-1690 (1991
71. Landoni, F., et al. Randomised study of radical surgery versus radiotherapy for stage Ib IIa cervical cancer. Lancet 350, 535-540 (1997
72. Crook, J. M., et al.comparison of health-related quality of life 5 years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial. J. Clin. Oncol. 29, 362-368 (2011
73. Yabroff, K. R., et al. Annual patient time costs associated with medical care among cancer survivors in the United States. Med. Care 52, 594-601 (2014
74. Hodges, J. C., et al. Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer. J. Oncol. Pract. 83 (3 Suppl.), e31s-e37s (2012
75. Fowler, J. F. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 44, 265-276 (2005
76. International Standard Randomised Controlled Trial Number Register. www.isrctn.com http://www.isrctn.com/ISRCTN17627211 (2015
77. Ramsay, C. R., et al. Statistical assessment of the learning curves of health technologies. Health Technol. Assess. 5, 1-79 (2001).